This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 19-22, 2025
Manchester Grand Hyatt San DiegoSan Diego, CA

Dr Shila Mekhoubad, PhD
Senior Director, Biology at Trace Neuroscience
Speaker

Profile

Shila Mekhoubad is head of Biology at Trace Neurosicence. Before that she led the cellular modeling group and the UNC13A ASO program at Maze Therapeutics. Previously she was at Biogen where her work supported several ALS and SMA drug discovery programs including Biogen’s Tofersen (SOD1-ALS), BIIB078 (C9ORF72-ALS), and the clinically approved ASO Spinraza for spinal muscular atrophy. Shila received her Bachelor’s degree in Molecular, Cell and Developmental Biology from UCLA. She completed her Ph.D. at Harvard University, where she trained in the laboratory of Dr. Kevin Eggan, working on the utility of iPSCs for disease modeling of neurological disorders.

Agenda Sessions

  • Correcting Aberrant Splicing of UNC13A As a Treatment for People with ALS

    2:00pm